A Phase I Study to Evaluate the Safety, Tolerability and PK, PD of Oral HRS9950 in Healthy Subjects With Single or Multiple Dose and Chronic Hepatitis B Patients With Multiple Dose, and Food Effects of HRS9950 in Healthy Subjects
Latest Information Update: 07 Jul 2022
At a glance
- Drugs HRS 9950 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Jiangsu Hengrui Medicine Co.
- 16 Jul 2020 New trial record